Skip to main content

Table 2 Pre-hospital, periprocedural and discharge medications, agiographic findings, and procedural results of the study patients stratified by the primary endpoint

From: Triglyceride glucose index for predicting cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes mellitus and acute coronary syndrome

Variable

No such events

n = 588

Primary endpoint

n = 188

P value

Medications before admission

 Aspirin, n (%)

432 (73.5)

146 (77.7)

0.251

 P2Y12 inhibitors, n (%)

231 (39.3)

79 (42.0)

0.505

 Lipid-lowering drugs, n (%)

430 (73.1)

144 (76.6)

0.346

 ACEI/ARBs, n (%)

180 (30.6)

74 (39.4)

0.026

 β-blockers, n (%)

227 (38.6)

71 (37.8)

0.837

 Insulin, n (%)

209 (35.5)

73 (38.8)

0.415

 Oral antidiabetic agents, n (%)

284 (48.3)

92 (48.9)

0.879

  Metformin, n (%)

144 (24.5)

44 (23.4)

0.762

  Alpha-glucosidase inhibitors, n (%)

123 (20.9)

31 (16.5)

0.185

  Sulfonylurea, n (%)

135 (23.0)

43 (22.9)

0.980

  Dipeptidyl peptidase 4 inhibitors, n (%)

8 (1.4)

4 (2.1)

0.687

 Any antidiabetic treatment, n (%)

419 (71.3)

143 (76.1)

0.199

Periprocedural medications

 Aspirin, n (%)

588 (100.0)

182 (96.8)

< 0.001

 P2Y12 inhibitors, n (%)

588 (100.0)

188 (100.0)

–

 Unfractionated heparin, n (%)

482 (82.0)

156 (83.0)

0.754

 Bivalirudin, n (%)

77 (13.1)

23 (12.2)

0.759

 GP IIb/IIIa receptor antagonist, n (%)

100 (17.0)

42 (22.3)

0.100

Medications at discharge

 Aspirin, n (%)

588 (100.0)

182 (96.8)

< 0.001

 P2Y12 inhibitors, n (%)

588 (100.0)

188 (100.0)

–

 Lipid-lowering drugs, n (%)

588 (100.0)

188 (100.0)

–

 ACEI/ARBs, n (%)

283 (48.1)

99 (52.7)

0.279

 β-blockers, n (%)

432 (73.5)

130 (69.1)

0.249

 Insulin, n (%)

188 (32.0)

76 (40.4)

0.033

 Oral antidiabetic agents, n (%)

318 (54.1)

100 (53.2)

0.831

 Metformin, n (%)

90 (15.3)

32 (17.0)

0.574

 Alpha-glucosidase inhibitors, n (%)

214 (36.4)

64 (34.0)

0.558

 Sulfonylurea, n (%)

146 (24.8)

42 (22.3)

0.488

 Dipeptidyl peptidase 4 inhibitors, n (%)

8 (1.4)

4 (1.2)

0.687

 Any antidiabetic treatment, n (%)

408 (69.4)

150 (79.8)

0.006

Angiographic findings

 One-vessel disease, n (%)

68 (11.6)

6 (3.2)

0.001

 Two-vessel disease, n (%)

164 (27.9)

30 (16.0)

0.001

 LM/three-vessel disease, n (%)

356 (60.5)

152 (80.9)

< 0.001

 Proximal LAD stenosis, n (%)

291 (49.5)

103 (54.8)

0.206

 Restenotic lesions, n (%)

61 (10.4)

49 (26.1)

< 0.001

 Chronic total occlusions, n (%)

136 (23.1)

40 (21.3)

0.597

 Trifurcation or bifurcation lesions, n (%)

450 (76.5)

148 (78.7)

0.534

 Heavy calcification lesions, n (%)

193 (32.8)

65 (34.6)

0.657

 Lesions > 20 mm long, n (%)

312 (53.1)

134 (71.3)

< 0.001

Procedural results

 Target vessel territory

 LM, n (%)

30 (5.1)

12 (6.4)

0.499

 LAD, n (%)

291 (49.5)

91 (48.4)

0.796

 LCX, n (%)

168 (28.6)

52 (27.7)

0.809

 RCA, n (%)

231 (39.3)

75 (39.9)

0.882

 DES use, n (%)

492 (83.7)

154 (81.9)

0.574

 BRS use, n (%)

27 (4.6)

5 (2.7)

0.246

 DCB use, n (%)

32 (5.4)

22 (11.7)

0.003

 Complete revascularization, n (%)

376 (63.9)

80 (42.6)

< 0.001

  1. ACEI angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker, LM left-main artery, LAD left anterior descending artery, LCX left circumflex artery, RCA right coronary artery, DES drug-eluting stent, BRS bioresorbable scaffold, DCB drug-coated balloon